Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2024 and highlighted recent business progress.

CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed ...

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

A research team from the Kunming University of Science and Technology, located in Southwest China's Yunnan province, has made ...

Melatonin promotes EMT in trophoblast cells via GDF15-mediated activation of the SMAD2/3 pathway and partially induces the expression of GPX4 through GDF15 to enhance oxidative damage resistance ...

Figure 1: A schematic diagram illustrating decidual NK cells as switchboards, licensed and educated to control trophoblast invasion and vascular remodeling and to interact with dendritic cells ...

Researchers at Concept to Medicine Biotech Co. Ltd., Lepu Biopharma Co. Ltd. and Shanghai Miracogen Inc. have described antibody-drug conjugates consisting of trophoblast glycoprotein (TPBG, ...

A study in Reproductive and Developmental Medicine links elevated levels of the KLF12 protein to impaired placental ...

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 ...